About Osiris
Osiris is a Healthcare company based in Baltimore (United States) founded in 1992, and was acquired by Smith & Nephew in March 2019. It operates as a stem cell-based regenerative medicines are developed and marketed. The company has 356 employees. Its focus areas include Life Sciences, Orthopedics, Drugs and Diversified. Its legal entity is OSIRIS THERAPEUTICS, INC. Its competitors include Horizon Therapeutics, Histogenics, Mesoblast, Osteal Therapeutics and Enobia Pharma and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Osiris Therapeutics was founded in 1992 in Baltimore, United States, based on stem cell technology from Case Western Reserve University. Operations focus on biotechnology within regenerative medicine, including bioengineering and viable tissue products. Commercial products such as BIO4, Cartiform, and Grafix are provided for orthopaedics, sports medicine, and wound care. Research and development continue to advance stem cell applications.
- Headquarters Baltimore, United States
- Employees 356
- SectorsHealthcare
- Website osiris.com
- Social LinkedIn X
- Acquired by Smith & Nephew (Mar 2019)
- Legal Name Osiris Therapeutics, Inc.
- Annual Revenue$142.82 M (USD)21as on Dec 31, 2018
- EBITDA$9.85 M (USD)595as on Dec 31, 2018
- Investors
- Employee Count356
- Acquired bySmith & Nephew
(Mar 2019)
Investors in Osiris
Osiris has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Smith & Nephew.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of knee, hip and shoulder joint replacements | 1856 | smith-nephew.com | London, United Kingdom |
Investor details for Osiris
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Osiris
44 people are tracked at Osiris (2 in leadership, 3 in board & advisors, 39 in team); the tracked headcount is 356.
| Name | Role | Group |
|---|---|---|
Sean Doyle | Regional Business Director | Leadership |
Paul Armstrong | Regional Business Director | Leadership |
Charles Reinhart Iii | Director | Board & advisors |
Peter Friedli | Chairman | Board & advisors |
Thomas J. Knapp | Director | Board & advisors |
Sal Alkes | Senior Regional Sales Specialist | Team |
Amanda R. | Revenue Analyst | Team |
Andrea Northen | Regional Sales Specialist | Team |
Ben Dease | Sales Representative | Team |
Brian Etter | Regional Sales Specialist | Team |
Kellie Mulkey | Regional Sales Specialist | Team |
ellen allocca | Surgical Sales Representative | Team |
Cory McAdams | Regional Sales Specialist | Team |
Jason Russell | Regional Sales Specialist | Team |
Heather Smith | Regional Sales Specialist | Team |
Lauren N. Roselli | Regional Sales Specialist | Team |
Mark McKone | Regional Sales Specialist | Team |
Neil Moore | Regional Sales Specialist | Team |
Ray Papcunik | Medical Device Sales Representative | Team |
Rick Ross | Regional Sales Specialist | Team |
24 more people are available in the full profile.
Complete people profiles for Osiris
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Osiris
2 dated milestones of Osiris across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Osiris is founded.
- Exit Acquired by Smith & Nephew.
Competitors of Osiris
Osiris has 10 listed competitors in our database, 9 of them funded. They include Horizon Therapeutics, Histogenics, Mesoblast, Osteal Therapeutics and Enobia Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| histogenics.com | 2000 | Waltham, United States | $115.72M | 69 | Restorative cell therapies for orthopedic diseases are developed. | |
| mesoblast.com | 2004 | Melbourne, Australia | – | – | Biotherapeutics derived from proprietary adult stem cell-based technologies | |
| ostealtx.com | 2013 | San Clemente, United States | $110.8M | – | Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections | |
| enobia.com | 1997 | Quebec, Canada | $138.52M | – | Therapies for genetic metabolic bone disorders are developed. | |
| cellbiomedgroup.com | 2001 | Cupertino, United States | $120M | – | Cellular therapeutics are developed for cancer, orthopaedics, and COPD. | |
| fibrocell.com | 1995 | Exton, United States | $34.66M | – | Developer of autologous cell and gene therapies for diseases of the skin, connective tissue and joints | |
| roosterbio.com | 2012 | Frederick, United States | $38.41M | 69 | Developer of human mesenchymal stem cells and extracellular vesicles | |
| angitiabio.com | 2018 | Woodland Hills, United States | $276M | – | Drugs for muscle, bone, and joint diseases are developed. | |
| scmlifescience.com | 2014 | Incheon, South Korea | $4.8M | – | Mesenchymal stem cells are developed for therapeutics using proprietary methods. |
Detailed competitors of Osiris
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Osiris
Websites that share an audience with Osiris (osiris.com).
Websites whose visitors overlap most with Osiris. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| athersys.com | 100% | 1.7K | #8,716,189 | View details | |
| mesoblast.com | 90% | 12.9K | #2,261,028 | View details | |
| ocutx.com | 75% | 12.7K | #1,928,176 | View details | |
| mimedx.com | 46% | 19.2K | #1,507,211 | View details | |
| geron.com | 46% | 11K | #2,181,363 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Osiris
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Orthopedics
10 companies that operate in the same segment as Osiris (Orthopedics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Prosthetic and orthotic devices are developed for individuals with disabilities. | 1919 | Duderstadt, Lower Saxony, Germany | USD 17 M | USD 1.97 B | 4,125 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | Dublin, Ireland | USD 61.78 M | USD 617.41 M | – | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Robotic arms are provided for mobility and rehabilitation support. | 2004 | Boston, Massachusetts, United States | USD 17.21 M | USD 40.93 M | 185 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608.25 M | – | 197 | |
Exoskeletons for medical rehabilitation and industrial productivity are provided. | 2005 | United States | USD 24.37 M | USD 71.6 M | 61 | |
Stabilization devices for healthcare are manufactured by the company. | 2005 | New York, New York, United States | USD 142.15 M | – | 43 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Osiris
Complete news archive for Osiris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Osiris
Osiris was founded in 1992.
Osiris is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Osiris has 356 employees.
Annual revenue of Osiris is $142.82M as on Dec 31, 2018.
Osiris Therapeutics was founded in 1992 in Baltimore, United States, based on stem cell technology from Case Western Reserve University. Operations focus on biotechnology within regenerative medicine, including bioengineering and viable tissue products. Commercial products such as BIO4, Cartiform, and Grafix are provided for orthopaedics, sports medicine, and wound care. Research and development continue to advance stem cell applications.
Osiris's top competitors include Horizon Therapeutics, RoosterBio and Mesoblast.
Osiris has 1 investor. Key investors include Smith & Nephew.
Osiris operates through Osiris Therapeutics, Inc..
Yes. Osiris was acquired by Smith & Nephew in March 2019.